… of lung injury and repair, and advances in supportive care, … ARDS therapies has been
further highlighted in the evolving COVID-19 pandemic, which causes severe acute respiratory …

… use of a variety of pharmacologic interventions for the treatment of ALI (Table 1). Some of
the early ARDSNet trials are indicative of much of the pharmacologic research aimed at ALI. …

… Personalized medicine targeting the different ARDS phenotypes has emerged as an option
… VILI and acute lung injury, as well as in patients with ARDS. Nevertheless, pharmacological …

… of lung injury have created the need to update the definition of experimental acute lung
injury (ALI). We queried 50 participants with expertise in ALI and acute respiratory distress …

… in disease progression and is preceded by acute lung injury (ALI) [19]. This distinction may
inform treatment … Emerging data show that SARS-CoV-2 may lead to damage to other organs …

… entities bronchopulmonary dysplasia, asthma and the different forms of acute lung injury
and chronic pulmonary diseases in adulthood. While clinical trials are so far restricted to …

… number of patients requiring ventilatory support for respiratory failure and acute lung injury
(ALI). As more data is emerging it has become apparent that COVID-19 also presents with a …

… acute lung injury and its most common cause, infectious pneumonia, can advance our approach
to precision targeted clinical interventions. … array of emerging therapies entering clinical …

… been demonstrated in other models of acute lung injuries [9]. The latter may be particularly
relevant for cytokine storm and it is likely that a combination of actions will be responsible. …

… biology dealing with the representation of disease mechanisms of action (ie. with the
pharmacology of drug targets). As an emerging interdiscipline combining experimental assays and …